Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

108.86 +14.00 (+14.76%)
Streaming Delayed Price Updated: 10:31 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corp

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Via Benzinga
Decoding 6 Analyst Evaluations For Blueprint Medicines
Via Benzinga
(BPMC) - Analyzing Blueprint Medicines's Short Interest
Via Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Blueprint Medicines's Earnings Outlook
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
Via Benzinga
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report. 
Via Investor's Business Daily
Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
Via Benzinga
Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. 
Via Talk Markets
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
The Latest Analyst Ratings for Blueprint Medicines
Via Benzinga
Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Why Blueprint Medicines Stock Soared Today
The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Blueprint Medicines's Earnings: A Preview
Via Benzinga
Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66  
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
What 15 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Why Shares of Blueprint Medicines Are Falling Wednesday
The company had generally improved earnings. 
Via The Motley Fool
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Biotech Stocks Using AI to Change Healthcare Forever
These three biotech firms are leveraging artificial intelligence to revolutionize therapeutics and make disease a thing of the past. 
Via InvestorPlace
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.